PHAR Stock News & Analysis | Latest Updates

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:PHAR) Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025.

September 3, 2025Investor Relations

Pharming Raises FY2025 Sales Guidance from $315.00M-$335.00M to $325.00M-$340.00M vs $324.30M Est

PHAR

May 8, 2025

Pharming Q1 EPS $(0.22) Misses $(0.01) Estimate, Sales $79.10M Beat $67.73M Estimate

PHAR

May 8, 2025

Pharming Group 2025 Raises Total Revenue Guidance To $325M-$340M (Prior $315M-$335M) vs. $324.3M Est.

PHAR

May 8, 2025

Pharming Q1 Sales $79.10M Beat $67.73M Estimate, Adj. Net Loss $7.1M

PHAR

May 8, 2025

Pharming Group Announces That The National Institute For Health And Care Excellence (Nice) Has Issued Positive Final Guidance Recommending Joenja (Leniolisib) Within The National Health Service In England And Wales For The Treatment Of Activated Phosphoin

PHAR

April 23, 2025

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

PHAR

March 21, 2025

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

PHAR

March 20, 2025

Pharming Doses First Patient In Phase II Trial of Leniolisib For CVID With Immune Dysregulation

PHAR

March 20, 2025

What Analysts Are Saying About Pharming Stock

PHAR

March 14, 2025

Oppenheimer Maintains Outperform on Pharming, Raises Price Target to $39

PHAR

March 14, 2025

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

PHAR

March 14, 2025

Pharming Q4 2024 GAAP EPADS $0.05 Beats $0.01 Estimate, Sales $92.70M Beat $80.74M Estimate

PHAR

March 13, 2025

Pharming Group Shareholders Approved The Appointment Of Mr. Fabrice Chouraqui As Executive Director And CEO For A Term Of 4-Years

PHAR

March 4, 2025

PHAR News

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

Pharming Raises FY2025 Sales Guidance from $315.00M-$335.00M to $325.00M-$340.00M vs $324.30M Est

Pharming Q1 EPS $(0.22) Misses $(0.01) Estimate, Sales $79.10M Beat $67.73M Estimate

Pharming Group 2025 Raises Total Revenue Guidance To $325M-$340M (Prior $315M-$335M) vs. $324.3M Est.

Pharming Q1 Sales $79.10M Beat $67.73M Estimate, Adj. Net Loss $7.1M

Pharming Group Announces That The National Institute For Health And Care Excellence (Nice) Has Issued Positive Final Guidance Recommending Joenja (Leniolisib) Within The National Health Service In England And Wales For The Treatment Of Activated Phosphoin

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

Pharming Doses First Patient In Phase II Trial of Leniolisib For CVID With Immune Dysregulation

What Analysts Are Saying About Pharming Stock

Oppenheimer Maintains Outperform on Pharming, Raises Price Target to $39

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

Pharming Q4 2024 GAAP EPADS $0.05 Beats $0.01 Estimate, Sales $92.70M Beat $80.74M Estimate

Pharming Group Shareholders Approved The Appointment Of Mr. Fabrice Chouraqui As Executive Director And CEO For A Term Of 4-Years